The study aims to find out whether a medication called BI 1291583 can help people with a lung condition called bronchiectasis. It will assess whether the medication can reduce the number of flare-ups (also called exacerbations) slow down worsening of lung function, and improve quality of life. This study includes people who have bronchiectasis, whether or not they have cystic fibrosis (CF). CF is a genetic condition that can lead to bronchiectasis, which is a long-term lung condition where the airways become widened and inflamed. In fact, bronchiectasis is the main way lung disease shows up in people with CF...
Study updates
Adult enrolment has now concluded. Study participation is still open to recruitment for adolescents (ages 12 to 17 years old)
Trials Tracker ID
TT014633
Age range
12 years and older
Length of participation
Participants will be in the study for up to about 20 months (86 weeks) and this includes the screening and follow-up period
This CF Week, we’re shining a light on the daily realities of living with cystic fibrosis. In this blog, Emily shares her #CFreality, the impact CF has on her physical and mental health, and how “the daily struggles remind me that every day I have now is a bonus.”
The Trust has funded and supported a wide range of research studies that have contributed to improvements in quality of life and survival for people with cystic fibrosis (CF) over the last 50 years
Vertex has made the decision to stop the investigation of the potential cystic fibrosis gene mRNA therapy (VX-522) and therefore terminated the VX21-522-001 trial. Despite efforts to improve tolerability of the multiple-ascending dose (MAD) portion of the study, including corticosteroids and reducing VX-522 dose, tolerability issues remained; Vertex has decided to not support the continuation of this study. mRNA therapy is a new type of treatment for people with CF, to be assessed in clinical trials. If you are aged between 18 and 65 and have CF mutations that mean you can’t take CFTR modulator treatments, you may be eligible...
Study updates
Screening for the Multiple Ascending Dose (MAD) part of this trial has now begun.
MAGNIFY is a new research study that aims to look at the lung health of people with cystic fibrosis over time by taking detailed pictures of the lungs using a type of clinical scan called Magnetic Resonance Imaging (MRI) which can detect small changes in the lungs when a special gas called Xenon is inhaled. It has been shown that these pictures can detect changes in how the lungs work in those living with cystic fibrosis before any changes are detected using standard measures of lung function. This study is funded by Cystic Fibrosis Trust and is part of the...
Today we announce the latest winners of our Helen Barrett Bright Idea Awards, named in memory of Helen Barrett, a successful entrepreneur with cystic fibrosis who, together with her partner, launched a gym that is still thriving today.
Tilly and Joseph are members of Cystic Fibrosis Trust’s Youth Advisory Group (YAG) and both live with CF diabetes (CFD). They spoke to Dr Ildem Akerman and Prof Victoria Salem about their Trust-funded research project investigating a novel type of treatment for CF diabetes.
Last week, the Association of the British Pharmaceutical Industry (ABPI) published a new report about medicine shortages in the UK. The report explains why shortages happen, how supply chains can be made stronger, and how patients can be better protected.
